Variable | Cases | Controls | p-valuea |
---|---|---|---|
Number of patients | 55 | 182 | |
Gender (male/female) (%) | 50/5 (91/9) | 167/15 (92/8) | |
Age at time of MI/index date median (IQR), years | 49 (42 – 57) | 50 (43 – 57) | |
Duration of HIV before MI/index date median (IQR), years | 10 (6 – 17) | 10 (7 – 16) | 0.71 |
Mean duration of therapy before MI/index date median (IQR), years | 6 (3 – 8) | 6 (3 – 9) | |
Intervals between plasma samples | |||
From sample 1 to initiation ART, median (IQR), days | 42 (24 – 76) | 49 (32 – 81) | |
From initiation of ART to sample 2 median (IQR), days | 99 (88 – 123) | 109 (87 – 142) | |
From sample 3 to MI/index date median (IQR), days | 334 (292 – 367) | 368 (334 – 408) | |
From sample 4 to MI/index date median (IQR), days | 52 (27 – 82) | 0 (0 – 0) | |
Smoking (never/ever) (%) | 2/53 (4/96) | 6/176 (3/97) | |
Blood pressure, systolic median (IQR) | 135 (120 – 149) n = 36 | 125 (115 – 140) n = 87 | 0.09 |
CD4 cell count/mm3, median (IQR)¤ | 496 (290–688) n = 52 | 547 (307–800) n = 161 | 0.78 |
HIV-RNA copies/mL, median (range)¤ | 39 (19–217200) | 39 (19–93900) | 0.08 |
Number of patients with HIV-RNA < 400 copies/mL¤ | 44 (80%) | 146 (89%) | 0.12 |
Creatinine μM, median (IQR)¤ | 81 (70–89) | 78 (70–88) | 0.38 |
mg/dL, median (IQR) | 1.1 (0.9–1.2) n = 48 | 1.0 (0.9–1.2) n = 148 | |
Cholesterol mM, median (IQR)¤ | 6.3 (5.5–8.0) | 5.7 (5.0–6.7) | 0.38 |
mg/dL, median (IQR) | 241 (214–309) n = 32 | 220 (193–255) n = 96 | |
Lipid-lowering treatment (%)# | 6 | 4 | 0.6 |
Starting antihypertensive treatment (%)# | 13 | 4 | 0.07 |
Starting anti-coagulative treatment (%)# | 4 | 3 | 0.67 |
Co-infected with hepatitis B (%) (HbsAg positive) | 6 | 7 | 0.6 |
Co-infected with hepatitis C (%) (HCV-Ab-positive) | 6 | 14 | 0.07 |
Exposed to ART (%)# | 100 | 100 | - |
Exposed to NRTI (%)# | 100 | 99.5 | 0.76 |
Exposed to abacavir (%)# | 56 | 39 | 0.007 |
Exposed to NNRTI (%)# | 73 | 58 | 0.006 |
Exposed to PI (%)# | 87 | 84 | 0.24 |